Wednesday, July 8, 2026

Drug profile · INN

diazoxide

diazoxide (DIAZOXIDE) is a potassium channel, inwardly rectifying, subfamily j, member 11 opener. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — diazoxide
US status
approved
Class
Route
INJECTION
Patents
0
Programs
1
Data quality
0.89

Quick answer

diazoxide (DIAZOXIDE) is a potassium channel, inwardly rectifying, subfamily j, member 11 opener. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN diazoxide
Brand DIAZOXIDE
Mechanism Potassium channel, inwardly rectifying, subfamily J, member 11 opener
Target ATP-sensitive inward rectifier potassium channel 11
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Potassium channel, inwardly rectifying, subfamily J, member 11 opener

Primary target: ATP-sensitive inward rectifier potassium channel 11

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. DCCR (diazoxide choline) extended-release tablets Phase 2 · SOLENO THERAPEUTICS · SH2B1 Deficiency Obesity

Frequently asked questions

What is diazoxide?

diazoxide (DIAZOXIDE) is a potassium channel, inwardly rectifying, subfamily j, member 11 opener. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for diazoxide?

DIAZOXIDE is a marketed brand name for diazoxide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of diazoxide?

diazoxide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.